EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Adjunctive Brexpiprazole in Patients With Unresolved Symptoms of Depression on Antidepressant Treatment Who are Early in the Disease Course: Post Hoc Analysis of Randomized Controlled Trials

Shivani Kapadia iD, Zhen Zhang, Csilla Csoboth, Mehul Patel, Michael E Thase, George I Papakostas

International Journal of Neuropsychopharmacology · 2025

DOI: 10.1093/ijnp/pyaf050 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Neuropsychopharmacology, 2025. Verfasst von Shivani Kapadia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, United States. Hauptthemen laut MEDLINE: Thiophenes, Major Depressive Disorder, Quinolones, Antidepressive Agents. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otsuka Pharmaceutical Development and Commercialization Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment for major depressive disorder (MDD) should be optimized as early as possible in the disease course to minimize patient suffering and maximize clinical benefits. This post hoc analysis aimed to investigate the efficacy and safety of adjunctive brexpiprazole in patients who were earlier and later in the disease course.

Methods

Data were pooled from three 6-week, randomized, double-blind, placebo-controlled trials of adjunctive brexpiprazole in adult outpatients with MDD and inadequate response to antidepressant treatment. “Earlier” and “later” disease course subgroups were defined based on proxies of median age, age at diagnosis, number of episodes, episode duration, and number of prior antidepressants. Efficacy was assessed by changes in Montgomery–Åsberg Depression Rating Scale (MADRS) total score, and safety by treatment-emergent adverse events.

Results

Greater improvement in MADRS total score at Week 6 (p<.05) was observed for antidepressant + brexpiprazole 2–3 mg/day (n = 579) versus antidepressant + placebo (n = 583) in all subgroups representing earlier and later disease, with treatment effects ranging from -1.79 to -2.92 points. The incidence of treatment-emergent adverse events across subgroups was 53.1–67.2% for antidepressant + brexpiprazole 2–3 mg/day and 43.0–51.8% for antidepressant + placebo, with no consistent differences in earlier or later disease.

Conclusions

Adjunctive brexpiprazole improved depressive symptoms earlier in the disease course, when benefits to patients and healthcare systems can be maximized. Adjunctive brexpiprazole also improved depressive symptoms later in the disease course; there was no advantage of delaying brexpiprazole treatment.

Trial registration

Post hoc analysis of NCT01360645, NCT01360632, NCT02196506 (ClinicalTrials.gov).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiophenesMajor Depressive DisorderQuinolonesAntidepressive AgentsOutcome Assessment, Health CareHumansMaleFemaleMiddle AgedAdultDouble-Blind MethodDrug Therapy, CombinationRandomized Controlled Trials as TopicAgedTreatment OutcomeDisease Progression

Stichwörter der Autor:innen

antidepressantbrexpiprazoledepressiondisease coursetreatment optimization

Substanzen

brexpiprazoleThiophenesQuinolonesAntidepressive Agents

Autor:innen und Institutionen

  • Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, United States.
  • Medical Affairs, Lundbeck LLC, Deerfield, IL, United States.
  • Perelman School of Medicine, University of Pennsylvania and the Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, United States.
  • Department of Psychiatry, Clinical Trials Network and Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.

ORCID-Profile: Shivani Kapadia

Förderung

  • Otsuka Pharmaceutical Development and Commercialization Inc.

Zitieren

APA

Kapadia, S., Zhang, Z., Csoboth, C., Patel, M., Thase, M. E., & Papakostas, G. I. (2025). Adjunctive Brexpiprazole in Patients With Unresolved Symptoms of Depression on Antidepressant Treatment Who are Early in the Disease Course: Post Hoc Analysis of Randomized Controlled Trials. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyaf050

Vancouver

Kapadia S, Zhang Z, Csoboth C, Patel M, Thase ME, Papakostas GI. Adjunctive Brexpiprazole in Patients With Unresolved Symptoms of Depression on Antidepressant Treatment Who are Early in the Disease Course: Post Hoc Analysis of Randomized Controlled Trials. International Journal of Neuropsychopharmacology. 2025. doi:10.1093/ijnp/pyaf050

BibTeX
@article{Kapadia2025,
  author = {Kapadia, Shivani and Zhang, Zhen and Csoboth, Csilla and Patel, Mehul and Thase, Michael E and Papakostas, George I},
  title = {Adjunctive Brexpiprazole in Patients With Unresolved Symptoms of Depression on Antidepressant Treatment Who are Early in the Disease Course: Post Hoc Analysis of Randomized Controlled Trials},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2025},
  doi = {10.1093/ijnp/pyaf050}
}
Kostenlos starten →